REVIEW



Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: Systematic review and meta-analysis

Jessica de Mattos Costa, Thiago Silva Torres ib, Lara Esteves Coelho and Paula Mendes Luz

Corresponding author: Thiago Silva Torres, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil 4365, 21045-900 Rio de Janeiro, Brazil. Tel: +5521 3865 9573. (thiago.torres@ini.fiocruz.br)

Abstract

Introduction: Optimal adherence to antiretroviral therapy is closely related with suppression of the HIV viral load in plasma, slowing disease progression and decreasing HIV transmission rates. Despite its importance, the estimated proportion of people living with HIV in Latin America and the Caribbean with optimal adherence has not yet been reported in a meta-analysis. Moreover, little is known of the factors leading to poor adherence which may be setting-specific. We present a pooled estimate of adherence to antiretroviral therapy (ART) of people living with HIV in Latin America and Caribbean, report the methods used to measure adherence and describe the factors associated with poor adherence among the selected studies.

Methods: We electronically searched published studies up to July 2016 on the PubMed, Web of Science and Virtual Health Library (Latin America and the Caribbean Regional Portal); considering the following databases: MEDLINE, LILACS, PAHO and IBECS. Two independent reviewers selected and extracted data on ART adherence and study characteristics. Pooled estimate of adherence was derived using a random-effects model. Risk of bias in individual studies was assessed independently by two investigators using the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS).

Results and discussion: The meta-analysis included 53 studies published between 2005 and 2016, which analysed 22,603 people living with HIV in 25 Latin America and Caribbean countries. Overall adherence in Latin America and Caribbean was 70% (95% CI: 63-76; $l^2 = 98\%$), similar to levels identified by studies conducted in high-income regions. Self-report was the most frequently used method to measure adherence. Subgroup analysis showed that adherence was higher for the shortest recall time frame used, as well as in countries with lower income level, Gross National Income (GNI) per capita and Human Development Index (HDI). Studies reported diverse adherence barriers, such as alcohol and substance misuse, depression, unemployment and pill burden.

Conclusions: Our study suggests that adherence to ART in Latin America and Caribbean may be below the sufficient levels required for a successful long-term viral load suppression.

Keywords: anti-HIV agents; antiretroviral therapy; Caribbean region; developing countries; highly active; Latin America; medication adherence

Additional Supporting Information may be found online in the Supporting information tab for this article.

Received 18 August 2017; Accepted 19 December 2017

Copyright © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

Latin America and the Caribbean (LAC) consists of 33 sovereign countries which cover an area that stretches from the northern border of Mexico to the southern tip of Chile, including the Caribbean. It has an area of over 20 million km², as of 2017, its population was estimated at approximately 650 million (~9% of the world population), being predominantly urban (80%) [1]. LAC is mostly a developing region which had a combined nominal gross domestic product (GDP) of 5,5 trillion USD and a GDP purchasing power parity (PPP) of 9.7 trillion USD in 2017 [2]. By 2015, the region's HDI was 0.731 (high), varying from 0.493 (Haiti, low) to 0.847 (Chile, very high) [3].

Antiretroviral therapy (ART) revolutionized the treatment of people living with HIV (PLHIV) by dramatically decreasing their morbidity and mortality [4]. In LAC region there were 2.1 million PLHIV and more than 1.1 million PLHIV on ART by the end of 2016 [5]. Indeed, studies have indicated promising results in the region with regards to the HIV Care Continuum: clinical retention, ART use and viral suppression significantly improved from 2003 to 2012 (63 to 77%, 74 to 91% and 53 to 82% respectively; p < 0.05, each), though disparities for vulnerable groups, such as female sex workers, people who

inject drugs, gay men and other men who have sex with men, remain [6].

Argentina, Bolivia, Brazil, Costa Rica, Mexico, Paraguay, Uruguay and Venezuela, in Latin America; and Antigua and Barbuda, Bahamas, Barbados, Saint Vincent and the Grenadines, and Trinidad and Tobago, in the Caribbean, have now adopted the World Health Organization recommendation of initiation of ART for all PLHIV irrespective of CD4 cell count [7]. ART coverage reaches 58% (95% confidence interval [95%CI] 42-72%) and 52% (95%CI 41-60%) of all PLHIV in LAC, respectively [7]. At the country level, treatment coverage was 70% in Cuba, followed by 64% in Argentina, 62% in Trinidad and Tobago and 60% in Brazil and Mexico. On the other hand, Bolivia had only 25%, Paraguay had 35% and Guatemala had 36% of PLHIV accessing treatment in 2016 [5]. From 2010 to 2016, the number of deaths has not dramatically decreased (12% of decrease in Latina America and 28% in the Caribbean) and, most significantly, the number of new infections remained relatively stable (0% of decrease in Latin America and 5% decrease in the Caribbean) [5]. This stability hides big differences between countries. In Latin America, although new infections have decreased by more than 20% in Colombia. El Salvador, Nicaragua and Uruguay, they increased significantly in Chile (34%), followed by Guatemala (23%), Costa Rica (16%), Honduras (11%) and Panama (9%); and slightly in Argentina and Brazil (3%). In the Caribbean, the majority of new infections occurred in Cuba, where estimated numbers of new HIV infections more than doubled between 2010 and 2016 [7], despite of the dramatic increase in treatment coverage [5].

The Political Declaration on Ending AIDS by 2030 [8] established specific goals for LAC region, which included reducing the number of new infections in LAC from 100,000 to 40,000 and increasing the number of PLHIV on ART from 1.1 to 1.6 million by 2020. Achievement of these goals will be challenging, requiring continued efforts from governments and international agencies.

Specifically, the HIV epidemic cannot be ended without containing the new infections, and adherence to ART plays an important role in this process. ART adherence is closely linked to suppression of the HIV viral load in plasma [9,10] which leads to immune reconstitution and also decreases onward HIV transmission [11]. The optimal adherence level to achieve viral suppression is unclear, though the 95% threshold established by Paterson et al. has largely been used as a goal [9]. More recently, other authors demonstrated that high levels of viral suppression could be obtained with adherence levels below 95% when in use of newer ART regimens [12-16]. The monitoring of ART adherence is highly recommended by health organizations [17] and the main methods are: selfreport by interview, pill counts, pharmacy refill and medication event monitoring system (MEMS). Monitoring patient's ART adherence is a challenging but critical way to identify those with poor adherence.

Even though there is a huge difference in socio-cultural characteristics across countries in LAC, there are still similar inequalities and traditional values that may act as barriers for HIV treatment, which may impact adherence to ART. This is more pronounced among high-risk populations, who are more vulnerable to social inequalities, discrimination and violence. However, little is known of the factors leading to poor

adherence which may be setting-specific. Although ART coverage has increased in the region, the fact that the number of new infections remained relatively stable may be related to the lack of adherence to ART.

In this meta-analysis, we synthesize the published peer reviewed literature, generating a pooled estimate of adherence to ART of PLHIV in LAC. In addition, we present the adherence proportion according to the country's income level, Human Development Index (HDI) rank, and Gross National Income (GNI) per capita, as well as other factors as detailed in the Methods section. We qualitatively synthetize the methods used to monitor adherence and describe the factors associated with poor adherence among the selected studies. Greater knowledge of ART adherence levels of PLHIV in LAC may provide means to improve patient care and could help Governments and regional institutions to accomplish the goal of ending AIDS by 2030.

2 | METHODS

This systematic review and meta-analysis has been reported according to the *Preferred reporting items for systematic reviews and meta-Analyses* (PRISMA) *Statement* [18].

2.1 | Protocol and registration

Key information about the design and conduct of this systematic review and meta-analysis are recorded at the international database of prospectively registered systematic reviews in health and social care (PROSPERO 2017:CRD4201705 5963) [19].

2.2 | Eligibility criteria

Studies of any design were included if they met all the following criteria: (i) the study involved people living with HIV/ AIDS in Latin America and the Caribbean (studies involving participants from other regions were included if we could clearly identify data from LAC participants); (ii) participants were receiving antiretroviral therapy; (iii) and treatment adherence was quantified. Studies were excluded if they included pregnant women and did not stratified adherence for the non-pregnant participants, because of specific features of their ART (treatment aimed at preventing vertical transmission of HIV and not as treatment of infection). Also, studies were excluded if they assessed alternative forms of treatment (for example, due to some specific co-infection), or if antiretrovirals were being used for post or pre-exposure prophylaxis. Similarly, we excluded studies focusing only on participants less than 18 years of age or specific populations (for example, only individuals previously found to have low adherence, or homeless populations). Studies including both adults and participants less than 18 years of age were not excluded if adherence data was stratified by age (and in this case, data from the age categories <18 years were not considered in the present analysis). Articles published before 2005 were excluded to avoid studies in the pre-HAART era. Also, grey literature was not considered in this study (such as thesis, dissertations, monographies, conference papers and reports).

2.3 Information sources and search strategy

Articles were identified through searches conducted on 14 July 2016 on PubMed, Web of Science and Virtual Health Library (Latin America and the Caribbean Regional Portal) considering the following databases: MEDLINE, LILACS, PAHO and IBECS. The search combined terms derived from four domains: (a) adherence; (b) HIV; (c) antiretroviral (d) countries of Latin America and the Caribbean (see Additional file 1 for the full PubMed search strategy). Citations were inserted into the study database when the four domains were jointly present in the title, abstract, MeSH terms or keywords. No limits were applied for language or publication date in the search. A reference manager (Zotero) was used to collect and organize search results and for duplicate removal.

2.4 Study selection

Two investigators (JMC, TST) reviewed all abstracts and fulltext articles independently, according to the eligibility criteria. Discrepancies were adjudicated by an independent third investigator (PML).

2.5 | Data collection process

Data extraction was performed independently by two investigators (JMC, TST) using a predefined extraction form. Each paper was coded for publication characteristics (authors, publication year, full title, journal and language), study characteristics (years when data was collected, country(ies) where the study was performed, study design, sample size, recruitment setting and number of study centres), participants characteristics (age, sex and race/ethnicity), adherence monitoring characteristics (method for adherence measurement, cutoff of optimal adherence, proportion of adherents, time frame used to measure adherence), and the factors significantly associated with adherence (p < 0.05) on multivariate modelling. Discrepancies in extracted data were adjudicated by an independent third investigator (PML).

2.6 Study definitions

Adherence was estimated for each study by dividing the number of individuals with optimal adherence by the number of individuals evaluated. This implies that our overall pooled adherence was based on the adherence threshold adopted in each study. When a study examined the effect of an intervention on ART adherence, only the adherence result at baseline was considered. In case there was no baseline assessment, only the first adherence assessment of the control group was extracted and analysed. As adopted in prior studies [20,21] when more than one adherence measurement was reported, the most objective method was chosen for the analysis (e.g. event monitoring system (MEMS) > pill medication count > pharmacy refill > self-reported adherence in the past week > self-reported adherence in the past month). When an optimal adherence threshold (e.g. ≥80 or ≥95%) was not explicitly defined in the study and adherence was categorized in levels (for example, low, regular and strict; or 65-84%, 85-94% and 95-100%), the highest adherence category was considered.

For subgroup analysis, adherence recall time frame was categorized in four periods: 3-4 days, 7 days, 30 days and 90 days. Location/country was classified by geographical area and categorized as: Brazil, South America (Chile, Colombia, Peru), Central America and Caribbean (Cuba, Dominican Republic, Guatemala, Haiti, Jamaica), North America (Puerto Rico and Mexico) and multi-region (included countries from more than one region). Time period when study was conducted was categorized as ≤2005, 2006–2010 and ≥2011. Study design was categorized as cross-sectional, longitudinal (non-RCT) and RCT. Income group was categorized by low/ lower middle, upper middle, high and mix, following the World Bank definitions for 2017 [22]. HDI and GNI per capita data were extracted from the Human Development Reports of the United Nations Development Programme [3]. The HDI is a composite index measuring average achievement in three basic dimensions of human development - a long and healthy life, knowledge and a decent standard of living [3]; while the GNI per capita reflects the average income of a country's citizens [3]. HDI ranking and the GNI per capita, were classified in two categories each (HDI: <0.754 and ≥0.754; GNI per capita in USD: <14.145 and >14.145). When a study involved multiple countries, the lower HDI or GNI value was considered, though we repeated the analysis considering the highest HDI and GNI values and the results changed minimally. Number of study sites was categorized as single-site, multi-site and online (participants accessed and completed survey via an online portal). Treatment experience was categorized as naïve (included individuals who had just recently started ART, usually within six months), experienced (included individuals who had been using ART for some time) and naïve and experienced. Instrument used to measure adherence were categorized as self-report, MEMS, self-report+drug refill and selfreport+pill count. Adherence threshold was categorized as <94% (when threshold was <24%, <280%, <285% or <290%), 95% (when threshold was ≥95%), 100% and not reported. Finally, the presence of statistical models evaluating factors associated with adherence (YES/NO) was evaluated in subgroup analysis.

2.7 | Risk of bias in individual studies

The quality of the included studies was assessed by two investigators (PML, LEC) using the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS) [23]. RoBANS includes criteria for judging the risk of bias for each domain. The risk of bias in a study was graded as low, high or unclear based on the following study features: selection of participants (selection bias), consideration of confounding variables (selection bias), measurement of exposure (detection bias), handling of incomplete outcome data (attrition bias) and selective outcome reporting (reporting bias).

2.8 Data synthesis

Logit transformation of the proportions and their standard errors were calculated to achieve a normal distribution which is required for the pooling of data [24]. Pooled adherence proportion was calculated using the DerSimonian-Laird method [25] assuming a random-effects model. Heterogeneity between studies was initially evaluated by visual inspection of forest-plots. The proportion of true heterogeneity to total variance was calculated by the Higgins I^2 statistic [26].

2.9 Additional analyses

We conducted subgroup analyses and estimated the pooled adherence proportion according to adherence recall time frame, location/country, time period when study was conducted, study design, country's income level, HDI rank, GNI per capita, sites, treatment experience, instrument to measure adherence, adherence threshold, and presence of statistical models evaluating factors associated with adherence.

3 | RESULTS

3.1 Study Characteristics

The flow diagram of study selection is shown in Figure 1. Fifty-three studies, composed of 22,603 participants in ART from 25 LAC countries, met eligibility criteria for the systematic review (Table 1) [27–79]. The median number of participants in ART per study was 201 [range: 13–3343; interquartile range (IQR): 394–125]. The studies were conducted between 2000 and 2013 and published from 2005 to

2016 in three different languages (English: 39; Spanish: 9; Portuguese: 5). Studies were mostly conducted in countries with an upper middle income level (81.1%).

Adherence was most commonly self-reported via structured interviews (96.2%). Forty-nine studies (92.4%), enrolling 21,974 participants, provided a self-reported adherence proportion. Forty-seven studies (88.7%) used self-report instruments only and one used MEMS only. Five studies (9.4%) used a combination of patient self-report, MEMS, pill count and drug refill. The following standardized instruments were used to measure self-reported adherence: the AIDS Clinical Trials Group (ACTG) adherence instrument [80]; the CAT-VIH - Cuestionario de adherencia al tratamiento para el VIH/SIDA [81]; the CEAT-VIH - Cuestionario para la Evaluación de la Adhesión al Tratamiento Antirretroviral [82]; the Morisky, Green & Levine Medication Adherence Scale [83]; the PMAQ -Patient Medication Adherence Ouestionnaire [84]: the SMAO - Simplified Medication Adherence Questionnaire [85] and the VPAD-24 - Variables psicológicas y comportamientos de adhesión [86]. Twenty-five studies (47.2%) did not report the instrument used or the instrument was designed for the study or adapted from other studies.

Two studies combined two different adherence measures reporting the overall optimal adherence proportion: Teixeira



Figure 1. Flow diagram of study selection for the meta-analysis of adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean, 2005–2016. LAC, Latin America and the Caribbean; PLHIV = people living with HIV.

				Adherence	Optimal adherence	Recall time	Country's		
Source	LAC country	Study design	N in analysis	measure (instrument)	threshold (%)	frame (days)	income group ^a	HDI ^b	GNI per capita ^b
Alave et al., 2013 [48]	Peru	Non-RCT longitudinal	1478	SR	>95	30	Upper middle	0.74	11,295
Allen et al., 2011 [38]	Antigua and Barbuda,	Cross-sectional	2/4	Y S	C.7 <i< td=""><td>~</td><td>Upper midale and high</td><td>0./.0-+c/.0</td><td>11,502 -28,049</td></i<>	~	Upper midale and high	0./.0-+c/.0	11,502 -28,049
	Grenada, Trinidad and								
	Tobago					0	-		
Amico et al., 2005 [29]	Puerto Rico	Cross-sectional	196	SR (modified ACTG)	64≤	CO	High	Not available	Not available
Aragonés et al. 2011 [39]	Cuba	Cross-sectional	781	SR	>95	7	Upper middle	0.775	7455
Arrivillaga et al., 2009 [36]	Colombia	Cross-sectional	269	SR	≥64	Not	Upper middle	0.727	12,762
						reported			
Balandrán et al., 2013 [56]	Mexico	Cross-sectional	2054	SR (ACTG)	≥95	4	Upper middle	0.762	16,383
Basso et al., 2013 [55]	Brazil	RCT	108	MEMS	≥95	30	Upper middle	0.754	14,145
Biello et al., 2016 [78]	17 countries ^c	Cross-sectional	1637	SR	100	30	Lower middle,	0.625-0.847	4466 –21,665
							upper middle		
	:	-			1		and high		
Bonolo et al., 2005 [27]	Brazil	Non-KCT longitudinal	306	SK	545	ŝ	Upper middle	0./54	14,145
Calvetti et al., 2014 [<mark>57</mark>]	Brazil	Cross-sectional	120	SR (CEAT-VIH)	Not	Not	Upper middle	0.754	14,145
					reported	reported			
Campbell et al., 2010 [<mark>37</mark>]	Guatemala	Cross-sectional	122	SR (VAS) >	≥95	7	Lower middle	0.64	7063
				Pill count					
Cardona-Arias et al., 2011 [40]	Colombia	Cross-sectional	146	SR (SMAQ)	Not	Not	Upper middle	0.727	12,762
	- (-	0		reported	reported		1 0 1 0	
Carrillo et al., 2007 [33]	COLORIDIA	CLOSS-SECTIONAI	T UC	¥О	ronortod	ronortod	upper miadie	0.727	12,702
Carvalho et al 2007 [32]	Brazil	Non-RCT Iongitudinal	150	с С	1 epoi (eu >95	1 chai rea	l Inner middle	0 754	14 145
Casotti et al., 2011 [41]	Brazil	Cross-sectional	81	SR (CEAT-VIH)	> 85	Not	Upper middle	0.754	14,145
						reported			
Costa et al., 2012 [<mark>19</mark>]	Brazil	RCT	13	MEMS >	>95	30	Upper middle	0.754	14,145
				Pill count > SR					
De Boni et al., 2016 [77]	6 countries ^d	Cross-sectional	3343	SR	Not	7	Lower middle,	0.625-0.847	4466–21,665
					reported		upper middle and high		
De La Hoz et al., 2014 [<mark>63</mark>]	Colombia	Cross-sectional	122	SR	>80	Not	Upper middle	0.727	12,762
						reported			

(Continued)	
÷	
Table	

				Adherence	Optimal adherence	Recall time	Country's		
Source	LAC country	Study design	N in analysis	measure (instrument)	threshold (%)	frame (days)	income group ^a	۹IDH	GNI per capita ^b
Drachler et al., 2016 [75]	Brazil	Non-RCT longitudinal	267	SR	≥95	30	Upper middle	0.754	14,145
Ferro et al., 2015 [64]	Peru	Cross-sectional	263	SR (VAS)	≥90	30	Upper middle	0.74	11,295
Fleming et al., 2016 [79]	Dominican	Cross-sectional	21	SR	100	Not	Upper middle	0.722	12,756
	Republic					reported			
Garcia et al., 2006 [30]	Brazil	Cross-sectional	182	SR (modified PMAQ)	>95	06	Upper middle	0.754	14,145
Gutierrez et al., 2012 [47]	Brazil	Cross-sectional	284	SR	100	3, 7	Upper middle	0.754	14,145
Hanif et al., 2013 [49]	Brazil	Cross-sectional	632	SR (modified	100	4	Upper middle	0.754	14,145
			4		-				
Harris et al., 2011 [42]	Lominican Republic	Cross-sectional	002	SK (VAS)	£77	30	Upper middle	0.722	12,/26
llias et al., 2011 [<mark>43</mark>]	Brazil	Cross-sectional	56	SR	>80	ന	Upper middle	0.754	14,145
lvers et al., 2014 [58]	Haiti	RCT	488	SR	100	30	Low	0.493	1657
Jacques et al., 2014 [59]	Brazil	Cross-sectional	152	SR (CEAT-VIH)	>85	Not	Upper middle	0.754	14,145
						reported			
Krishnan et al., 2015 [65]	Peru	Cross-sectional	313	SR (VAS)	≥90	Not	Upper middle	0.74	11,295
						reported			
Magidson et al., 2015 [66]	$17 \text{countries}^{\text{e}}$	Cross-sectional	2211	SR	100	30	Lower middle,	0.625-0.847	4466–21,665
							upper middle		
							and high		
Magidson et al., 2016 [74]	Brazil	Cross-sectional	182	SR	Not reported	06	Upper middle	0.754	14,145
Malbergier et al., 2015 [<mark>67</mark>]	Brazil	Cross-sectional	438	SR (SMAQ)	Not reported	7	Upper middle	0.754	14,145
Malow et al., 2013 [50]	Haiti	Cross-sectional	194	SR	Not reported	Not	Low	0.493	1657
						reported			
Mascolini et al., 2008 [33]	6 countries ^f	Cross-sectional	592	SR	Not reported	30	Upper middle	0.722–0.827	8350–20,945
							and high		
Muñoz et al., 2011 [44]	Peru	Non-RCT Iongitudinal	60	SR (ACTG)	≥95	30	Upper middle	0.74	11,295
Nachega et al., 2012 [46]	Brazil	Cross-sectional	201	SR (ACTG)	100	30	Upper middle	0.754	14,145
Pacífico et al., 2015 [73]	Peru	Cross-sectional	364	SR (SMAQ)	Not reported	Not	Upper middle	0.74	11,295
				+Withdrawal ^g		reported			
Padoin et al., 2013 [51]	Brazil	Cross-sectional	125	SR	100	7	Upper middle	0.754	14,145
Pérez-Salgado et al., 2015 [68]	Mexico	Cross-sectional	557	SR	>95	7,30	Upper middle	0.762	16,383
Piña López et al., 2008 [34]	Mexico	Cross-sectional	64	SR (VPAD-24)	100	30	Upper middle	0.762	16,383

_
(Continued
÷
<u>e</u>
_ab

Course		Study dacium	n in sulficie	Adherence measure	Optimal adherence threshold	time frame	Country's income	e C T	GNI per
Remian at al 2007 [31]	Brazil	Croce-certional		S.R. (modified	00~	6 fam) o	l Inner middle	0 75.4	11115
			0004	ACTG)		C		t	トー, エーノ
Santillán Torres Torija ot al 2015 [20]	Mexico	Cross-sectional	109	SR (modified	100	30	Upper middle	0.762	16,383
et al., 2010 [07] Santos et al., 2005 [28]	Brazil	Cross-sectional	394	SR	Not reported	Not	Upper middle	0.754	14,145
						reported			
Silva et al., 2014 [60]	Brazil	Cross-sectional	314	SR (CEAT-VIH)	≥85	Not reported	Upper middle	0.754	14,145
Silveira et al., 2014 [62]	Brazil	RCT	332	SR	≥95	e	Upper middle	0.754	14,145
Souza et al., 2016 [76]	Brazil	Cross-sectional	140	SR (CEAT-VIH) > Withdrawal	Not reported	7	Upper middle	0.754	14,145
Teixeira et al., 2013 [52]	Brazil	Non-RCT longitudinal	144	Pill count+SR (ACTG) ^h	≥95	Not reported	Upper middle	0.754	14,145
Tello-Velásquez et al., 2015 [70]	Peru	Cross-sectional	389	SR (CEAT-VIH)	Not reported	Not reported	Upper middle	0.74	11,295
Tietzmann et al., 2013 [<mark>53</mark>]	Brazil	Cross-sectional	453	SR	≥95	m	Upper middle	0.754	14,145
Tufano et al., 2015 [71]	Brazil	Cross-sectional	438	SR (SMAQ)	Not reported	7, 90	Upper middle	0.754	14,145
Varela et al., 2014 [61]	Chile	Cross-sectional	120	SR (Morisky	Not reported	Not reported	High	0.847	21,665
				-Green-Levine)					
Varela-Arévalo et al., 2013 [54]	Colombia	Cross-sectional	127	SR (CAT-VIH)	>90	Not reported	Upper middle	0.727	12,762
Zulliger et al., 2015 [72]	Dominican Republic	Cross-sectional	194	SR (ACTG)	100	4	Upper middle	0.722	12,756
ACTG, Aids Clinical Trials Grou MEMS, medication event monitc self-report; VAS, visual analogue	ıp; CAT-VIH, Cuest pring system; PMA scale;	ionario de adherencia al Q. Patient Medication ,	tratamiento para Adherence Quest	i el VIH/SIDA; CEA cionnaire; RCT, ranc	T-VIH, Cuestionar domized clinical t	io para la Evalua rials; SMAQ, Sim	<i>ción de la Adhesi</i> plified Medicatio	ión al Tratamie. n Adherence C	nto Antirretroviral; Questionnaire; SR,
^a Study countries were categorize ^b Study countries were categorize ity in constant 2011 internationa	ed according to the ed according to the al dollars), as define	 income group, as defined in the second second	ned by the World n Development I S Development I	Bank for 2017 [22 ndex (HDI) ranking Programme [3]	!]. and the Gross N	lational Income (SNI) per capita (I	based on purch	lasing power par-
^c Argentina, Bolivia, Brazil, Chile,	Colombia, Costa Ri	ca, Ecuador, El Salvado	, Guatemala, Hor	nduras, Mexico, Nic	aragua, Panama, F	^D araguay, Peru, U	ruguay and Vene	ezuela.	

^dArgentina, Brazil, Chile, Honduras, Mexico and Peru.

²Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay and Venezuela. Argentina, Brazil, Dominican Republic, Jamaica, Mexico and Puerto Rico.

⁸Used two methods to measure adherence, self-report or medication withdrawal, to calculate study proportion of participants in optimal adherence. "Used two methods to measure adherence, self-report and pill count, to calculate study proportion of participants in optimal adherence.

Costa JDM et al. Journal of the International AIDS Society 2018, 21:e25066 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25066/full | https://doi.org/10.1002/jia2.25066 et al. (2013)[52] (ACTG questionnaire and pill count) and Pacífico et al. (2015)[73] (SMAQ guestionnaire or drug refill). Balandrán et al. (2013) [56], assessed adherence using the ACTG questionnaire (5 items) and the adherence index, but only the results for the ACTG questionnaire were considered in this meta-analysis. Though as a general rule we opted to use reported data from the most objective methods, a few exceptions were made. Campbell et al. (2010) [37] used both self-report (Visual Analogue Scale [VAS]) and pill count for measuring adherence. Although pill count was the most objective measure, the time frame information for it was not available, thus only data from the seven-day recall self-report measure (VAS) was considered in the analysis. In Souza et al. (2016) [76], only the self-reported adherence measure was considered because the adherence as measured from medication dispensing data addressed a period greater than three months (the whole study period).

Studies used different thresholds to define optimal adherence (range: \geq 64% to > 100%). The most common definitions used for optimal adherence were higher than 95% and 100% of prescribed doses (54.7%). Adherence recall time frames varied between the last three days and the last 90 days. Seventeen studies (32.1%) did not clearly report the time frame used.

Twenty-four out of 53 studies evaluated factors associated with adherence using adjusted statistical models. Statistically significant factors (p < 0.05) associated with adherence to ART found by these studies are presented in Table 2. Some factors positively associated with adherence to ART were: high social support [32,49], good relationship with the physician [39,68]; satisfaction with the healthcare service [32,72]; and use of counselling services [38]. Some factors negatively associated with adherence to ART were: alcohol use or alcohol use disorders [27,38,52,64,77]; substance use [52,72,77,78]; high pill burden [27,47,62]; depression symptoms [61,62,71]; unemployment or irregular employment [27,62]; and high or detectable HIV viral load [62,71].

3.2 Risk of Bias

The results of the risk of bias assessment for each study included in the meta-analysis are shown in Figure 2. The risk of selection biases due to the inadequate selection of participants was high in 43 studies, low in three and unclear in seven. The risk of selection biases due to the inadequate confirmation and consideration of confounding variables during the design and analysis phases was low in 36 studies, but high in the remaining 17. The risk of performance biases caused by inadequate measurements of exposure was low in 50 studies, high in two and unclear in one. The risk of attrition biases caused by the inadequate handling of incomplete outcome data was low in 47 studies and high in the remaining six. The risk of selective reporting bias was low in all studies.

3.3 Meta-analysis

The overall pooled adherence was estimated in 70% (95% CI: 63–76; $l^2 = 98\%$) (Figure 3). Results differed when we stratified studies by the four pre-defined time frames: last 3–4 days, last 7 days, last 30 days and last 90 days. The pooled estimate for the shortest period was significantly 7 higher and

somewhat less heterogeneous (80%; 95% CI: 74–85; $I^2 =$ 93%) than for the longest period (55%; 95% CI: 26–81; $I^2 =$ 96%) (Figure 4). We also recalculated the pooled proportion according to the location/country, and in Brazil, where most of studies were conducted (45.3%), the adherence estimate was 64% (95% CI: 54–73; $I^2 =$ 98%) (Figure 5).

Results of the subgroup analysis are shown in Table 3. Studies conducted in low or lower middle income countries showed a higher pooled adherence (83%; 95% CI: 63-93; I^2 = 81%) than in middle income countries (70%; 95% CI: 62– 77; I^2 = 98%). In countries with a lower HDI (<0.754), pooled adherence was higher (75%; 95% CI:64–84; I^2 = 99%) than in countries with a higher HDI (66%; 95% CI: 57–74; $I^2 = 98\%$). Similarly, in countries with a lower GNI per capita (<\$ 14,145) the pooled adherence was higher (75%; 95% CI: 65-83; I^2 = 99%) than in countries with a higher GNI per capita (65%: 95% CI: 55–74: 1² = 98%). Studies addressing only ART naïve participants had lower pooled adherence (56%; 95% CI: 33–78; $I^2 = 75\%$) than those including treatment experienced participants (69%; 95% CI: 62–75; I² = 98%). The pooled proportion of adherence for studies using patient's self-report was 71% (95% CI: 64–77: I^2 = 99%), guite similar to the overall results as expected given that self-report was the most frequent tool used to measure adherence (96.2%).

4 | DISCUSSION

This is the first systematic review and meta-analysis that estimates a pooled proportion of adherence to ART in LAC, uniting evidence from 53 studies, 22,603 participants, in 25 countries. Results suggest that overall, 70% (95% CI: 63-76) of PLHIV in LAC were adherent to ART and, consequently, that 30% of PLHIV in LAC may be at risk of developing AIDSrelated illnesses and transmitting the virus to others because they cannot achieve sufficient adherence to ART as required for successful viral load suppression. Mills et al. (2006) [87], in a meta-analysis of adherence to ART in sub-Saharan Africa (27 studies; 12,116 participants) and Mhaskar et al. (2013) in a meta-analysis of adherence to ART in India (8 studies; 1666 participants)[88], found similar estimates for other low/middle income regions (77%; 95% CI: 68-85; I² = 98.4% and 70%; 95% CI: 59–81, I^2 = 96.3% respectively) than that found by our study. Pooled proportion of adherence has also been estimated by other researchers for North America (55%)[87]; Spain (55%)[89]; worldwide (62%)[90]; and for high-risk subgroups living with HIV such as drug users (60%)[91], pregnant women (73.5%)[92]; female sex workers (76%) [93], adolescents (62%) [20], prisoners (54.6%) [94] and different highrisk populations living with HIV in China (77.61%) [95].

Our results show that, when assessing adherence, depending on the time-frame for recall, different results might be achieved. Our results point to higher adherence (80%) in the shortest time frame and lower adherence (55%) in the longer time-frame. These findings are consistent with the meta-analysis of adherence among HIV-positive drug users, conducted by Malta et al. (2010) [91], where the pooled estimate for the shortest period was higher (71%) than the pooled estimated for the intermediate period (54%). Moreover, and again, similarly to Malta et al. (2010) [91], the shortest time frame also yielded a less heterogeneous estimate of adherence. Taken

Table 2. Factors associated with adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean, for 24 studies with available data, 2005–2016

Source	Factors associated with adherence
Allen et al., 2011 [38]	Use of a counselling service (AOR = 3.20; 95% CI: 1.55–6.61; $p = 0.002$) Revelation of HIV status without consent (AOR = 2.31; 95% CI: 1.13–4.74; $p = 0.023$) Alcohol consumption (AOR = 0.47; 95% CI: 0.23–0.96; $p = 0.039$) Side effects (AOR = 0.22; 05% CI: 0.15, 0.42; $p = 0.002$)
Aragonés et al., 2011 [<mark>39</mark>]	Communication with the physician (AOR = 1.457 ; 95% CI: $1.010-2.103$; $p = 0.044$) Change in treatment (AOR = 1.597 ; 95% CI: $1.083-2.358$; $p = 0.018$) Memory (AOR = 3.175 ; 95% CI: $2.112-4.774$; $p = 0.000$) Self-efficacy (AOR = 2.976 ; 95% CI: $1.999-4.433$; $p = 0.000$) Commitment to treatment (AOR = 1.597 ; 95% CI: $1.093-2.334$; $p = 0.016$)
Arrivillaga et al., 2009 [36]	Confidence in treatment (AOR = 1.817 ; 95% CI: $1.245-2.850$; $p = 0.002$) Membership in the subsidized national health care plan ^a or being uninsured (AOR = 3.478 ; 95% CI: $1.957-6.181$; $p < 0.0001$) when compared to the contributive plan.
Biello et al., 2016 [78]	Age (AOR = 1.02; 95% CI: 1.00–1.03; p = 0.04) Hard drug use during sex (AOR = 0.72; 95% CI: 0.53–0.96; p = 0.03)
Bonolo et al., 2005 [27]	(Nonadherence) Unemployment (ARH = 2.17; 95% CI: 1.19–3.96; $p = 0.011$) Alcohol use (ARH = 2.27; 95% CI: 1.58–3.25; $p < 0.001$) Self-report of three or more adverse reactions (ARH = 1.64; 95% CI: 1.09–2.48; $p = 0.017$) Number of pills per day (ARH = 2.04; 95% CI: 1.11–3.76; $p = 0.02$) Switch in antiretroviral regimen (ARH = 2.72; 95% CI: 1.84–4.03; $p < 0.001$) Use of more than one health service (RH = 0.54; 95% CI: 0.36–0.80; $p = 0.002$) Longer time between HIV test and 1st prescription (ARH = 2.27; 95% CI: 1.52–3.40; $p < 0.001$)
Calvetti et al., 2014 [57]	Social class (middle) (AOR = 3.5250; 95% CI: 1.229–10.080; p = 0.019) Perceived HIV stage (symptomatic) (AOR = 0.346; 95% CI: 0.138–0.871; p = 0.024) WHOQOL-HIV bref ^b domain I/physical ^c (AOR = 1.276; 95% CI: 1.010–1.613; p = 0.041) WHOQOL-HIV bref ^b domain V/environment ^c (AOR = 1.415; 95% CI: 1.158–1.728; p = 0.001)
Carvalho et al., 2007 [32]	(Nonadherence) Lower educational level (AOR = 18.4; 95% CI: 2.9–118.8; $p = 0.002$) Profession (AOR = 0.2; 95% CI: 0.0–0.9; $p = 0.047$) Income (AOR = 1.0; 95% CI: 1.0–1.0; $p = 0.007$) High social support (AOR = 10.6; 95% CI: 1.4–79.1; $p = 0.022$) Satisfaction with the service at the pharmacy (AOR = 32.5; 95% CI: 4.6–227.9; $p = 0.000$) Healthcare reference centre in <i>Plano Piloto</i> (an urban planned location vs. unplanned) (AOR = 0.2; 95% CI: 0.1–0.7; $p = 0.014$)
Casotti et al., 2011 [41]	Higher educational level (AOR = 1.40; 95% CI: 1.10–1.78; <i>p</i> = 0.006) longer duration of undetectable viral load (AOR = 1.03; 95% CI: 1.00–1.06; <i>p</i> = 0.02)
De Boni et al., 2016 [77]	(Nonadherence - missed doses) Substance use ($p < 0.001$): alcohol use compared to no substance use (AOR = 2.46; 95% CI: 1.99–3.05) illicit drug use compared to no substance use (AOR = 3.57; 95% CI: 2.02–6.30) using both alcohol and illicit drugs compared to no substance use (AOR = 4.98; 95% CI: 3.19–7.79) HIV transmission mode ($p < 0.001$): homosexual vs. heterosexual (AOR = 0.88; 95% CI: 0.67–1.16) IDU vs. heterosexual (AOR = 2.46; 95% CI: 1.04–5.83) others vs. heterosexual (AOR = 1.44; 95% CI: 1.05–1.98) Age (per ten years increase) (AOR = 0.88; 95% CI: 0.80–0.98; $p = 0.02$) Study site (AOR = 1.87; 95% CI: 1.17–3.01 for IHSS/HE-Honduras vs. FH-Argentina AOR = 0.08; 95% CI: 0.04–0.16 for INCMNSZ-Mexico vs. FH-Argentina; $p < 0.001$)
Drachler et al., 2016 [75]	(Nonadherence) SEA-ART ^d score (per each unit increase) (AOR = 0.92; 95% CI: 0.90–0.95; p = 0.002)

Table 2. (Continued)

Source	Factors associated with adherence
Ferro et al., 2015 [64]	Having an alcohol use disorder with optimal adherence (AOR = 0.427; 95% CI: 0.187–0.976; $p = 0.044$)
	Having an alcohol use disorder with perfect adherence (AOR = 0.552; 95% CI: 0.327–0.930; $p = 0.026$)
Gutierrez et al., 2012 [47]	Having symptoms prior to ART ($p = 0.039$)
	Taking fewer ART pills ($p = 0.003$)
	Not missing medical appointments ($p < 0.0001$)
Hanif et al., 2013 [<mark>49</mark>]	Having one child (compared to 0 or \geq 2) (AOR = 2.29; 95% CI: 1.33–3.94; p = 0.003)
	High social support (AOR = 2.85; 95% CI: 1.50–5.41; <i>p</i> = 0.001)
	High asset index (AOR = 2.47; 95% CI: 1.79–3.40; <i>p</i> = 0.000)
	Gender female (AOR = 0.58; 95% CI: 0.38–0.88; p = 0.011)
Pérez-Salgado et al., 2015 [<mark>68</mark>]	(Low adherence)
	Patient dissatisfaction about relationship with the physician (AOR = 1.90; 95% CI: 1.01–3.57; $p = 0.046$)
Piña López et al., 2008 [34]	The combination of intermediate levels of stress associated with tolerance to ambiguity and low levels of depression ($p = 0.027$)
Remien et al., 2007 [<mark>31</mark>]	(Nonadherence)
	Sexual orientation (heterosexual vs. homosexual/bisexual) (AOR = 2.69; 95% CI: 1.08–6.66; $p < 0.05$)
	Difficulty to tailoring the rapeutic regimen to daily routine (AOR = 2.56; 95% CI: 1.07–6.14; p < 0.05)
	Loss of appetite in the last month (AOR = 3.56 ; 95% CI: $1.31-9.62$; $p < 0.05$)
Silveira et al., 2014 [<mark>62</mark>]	No regular employment (ARR = 0.91; 95% CI: 0.82–1.00; <i>p</i> = 0.05)
	Detectable plasma viral load (ARR = 0.83; 95% CI: 0.73–0.95; p = 0.01)
	Depressive symptoms (ARR = 0.99; 95% CI: 0.99–1.00; p = 0.04)
	Number of tablets daily (ARR = 0.96; 95% CI: 0.93–0.98; $p < 0.01$)
Teixeira et al., 2013 [<mark>52</mark>]	Intensity of alcohol use (AOR = 3.29; 95% CI: 1.83–5.92; <i>p</i> < 0.001)
	Use of alcohol and multiple substances (AOR = 5.99; 95% CI: $1.78-20.28$; $p = 0.004$)
Tello-Velásquez et al., 2015 [70]	(Nonadherence)
	Moderate/severe poor quality of sleep (APR = 1.34; 95% CI: 1.17–1.54; $p = 0.001$)
Tietzmann et al., 2013 [53]	Gender male (APR = 1.37 ; $1.24-1.52$; $p = 0.000$)
	Low and moderate clinical status (compared to severe) (APR = 1.18 ; 95% CI: $1.04-1.35$; $p = 0.009$)
Tufano et al., 2015 [71]	Nonadherence in last seven days:
	Age in years (AOR = 0.96; 95% CI: 0.93–0.98; p < 0.01)
	Hamilton Depression Rating Scale (AOR = 1.04; 95% CI: 1.01–1.07; $p < 0.01$)
	Viral load (AOR = 1.21; 95% CI: 1.03–1.42; p < 0.05)
	Nonadherence in last 90 days:
	Age in years (AOR = 1.02; 95% CI: 1.00–1.05; <i>p</i> < 0.05)
	Viral load (AOR = 1.21; 95% CI: 1.03–1.42; $p < 0.05$)
	Heterosexual HIV transmission mode (compared to homo/bisexual) (AOR = 0.52; 95% CI: 0.28– 0.96; $p < 0.05$)
	Unknown HIV transmission mode (compared to homo/bisexual) (AOR = 0.10; 95% CI: 0.01–0.88; p < 0.05)
	CD4 + cell count (AOR = 0.99; 95% CI: 0.99–1.00; $p < 0.05$)
Varela et al., 2014 [61]	Nonadherence:
	Moderate-severe depressive symptoms [Exp(B) = 3.08; 95% CI: 1.08–8.80; $p = 0.023$]
Varela-Arévalo et al., 2013 [<mark>54</mark>]	Barriers to treatment (AOR = 7.9; 95% CI: 2.04–30.59; p = 0.003)
	Men with no family member with HIV (AOR = 0.10; 95% CI: 0.01–0.73; $p = 0.023$)
	Women with no family member with HIV (AOR = 0.05; 95% CI: 0.00–0.73; $p = 0.028$)

Table 2. (Continued)

Source	Factors associated with adherence
Zulliger et al., 2015 [<mark>72</mark>]	Nonadherence:
	'Female sex worker'-related discrimination (AOR = 3.24; 95% CI: 1.28–8.20; $p \le 0.05$)
	Use of any drug (AOR = 2.41; 95% CI: 1.09–5.34; $p \le 0.01$)
	Worked in a 'Female sex worker' establishment (AOR = 2.35; 95% CI: 1.20–4.60; $p \le 0.05$)
	Internalized stigma related to female sex work (AOR = 1.09; 95% CI: 1.02–1.16; $p \leq 0.05$)
	Positive perceptions of HIV providers (AOR = 0.91; 95% CI: 0.85–0.98; $p \le 0.05$)

AOR, adjusted odds ratio; APR, adjusted prevalence ratio; ARR, adjusted relative risk; ARH, adjusted relative hazard; IDU, injection drug use. ^aGeneral System of Social Security in Health (*Sistema General de Seguridad Social en Salud*, SGSSS - Colombia).

^bWHOQOL-HIV bref is a shorter version of the original instrument WHOQOL-HIV, a multi-dimensional instrument designed to assess the quality of life of people infected with human immunodeficiency virus (HIV).

^cDomain I of WHOQOL-HIV bref includes physical pain, physical problem, energy and sleep quality; and domain V includes physical safety, housing, finance, care (access to quality health care and social services), information, leisure time, physical environment (pollution/noise/transit/climate) and transport.

^dThe scale of Self-efficacy Expectations of Adherence to Antiretroviral Treatment (SEA-ART) assesses patients' expectations of their own ability to follow the antiretroviral prescription in 21 high-risk situations for non-adherence to ART.



Figure 2. Risk of bias of studies included in the meta-analysis of adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean, 2005–2016, presented as percentages across all included studies.

together, these findings suggest that a shorter time frame might yield estimates that are less prone to recall bias and thus more accurate. Conversely, a longer time interval increases the chances of adherence issues, what may not be observed using a shorter time frame. That said, which adherence time frame best predicts virological failure is less known, with a few studies suggesting that the impact of the time frame might be minimal [21,96].

There were no significant differences in the pooled adherence among different optimal adherence thresholds (<94%, 95%, 100%), which was similar to the findings of Ortego et al. (2011) [90]. Moreover, in a recent meta-analysis conducted by Bezabhe et al. (2016)[21], there were no significant differences in the pooled odds ratios for virological failure among different optimal adherence thresholds (OR $_{\geq98-100\%}$ = 0.54, 95% CI: 0.29–1.00, I^2 = 85%; OR $_{\geq95\%}$ = 0.34, 95% CI: 0.24–0.47, I^2 = 92; OR $_{\geq80-90\%}$ = 0.34, 95% CI: 0.23–0.51, I^2 = 0%) showing that irrespective of the cutoff point, optimal adherence to ART was associated with positive clinical outcomes.

As per Marmot, health inequalities are perhaps the most damning indictments of social and economic inequalities [97].

Similar social gradients in health can be observed if we stratify the population by region, country or income. Social determinants of health can greatly affect adherence to ART. The proportion of people who reported optimal adherence to ART varied according to the country's income level, HDI and GNI per capita. We found that in studies from lower income countries the pooled proportion of adherence was higher than in studies from middle income countries. HDI and GNI per capita followed the same trend. Studies in countries with a lower HDI and GNI per capita had higher proportions of adherence than studies in countries with a higher HDI and GNI per capita. These findings are consistent with previous meta-analysis: Uthman et al. (2014) [98] found that the proportion of PLHIV who achieved good adherence was significantly higher in lower-income countries (86%) compared to higher-income countries (67.5%; p < 0.05). Although our findings suggest that less developed countries can achieve the same or higher level of adherence than more developed ones, huge differences between populations and availability of healthcare may have been included in each setting (selection bias). It is possible that in lower-income countries participation in a research

Study	# Adherents	Total		Adherence %	95% CI	Weight
1	1453	1478	: 1	• 0.98	[0.98; 0.99]	1.9%
2	205	274	֥-	0.75	[0.69; 0.80]	1.9%
3	156	196		0.80	[0.73; 0.85]	1.9%
4	557	781	+	0.71	[0.68; 0.74]	2.0%
5	153	269		0.57	[0.51; 0.63]	1.9%
6	1783	2054	+	0.87	[0.85; 0.88]	2.0%
7	47	108	—•— :	0.44	[0.34; 0.53]	1.9%
8	904	1637	+	0.55	[0.53; 0.58]	2.0%
9	193	306	:	0.63	[0.57; 0.68]	1.9%
10	58	120		0.48	[0.39; 0.58]	1.9%
11	108	122		0.89	[0.81; 0.94]	1.8%
12	109	140		0.75		1.9%
13	115	103		0.50	[0.40, 0.60]	1.9%
14	34	81		0.77	[0.09, 0.03]	1.9%
16	8	13		0.42	[0.32: 0.86]	1.5%
17	2773	3343		0.83	[0.82: 0.84]	2.0%
18	112	122		0.92	[0.85; 0.96]	1.8%
19	186	267		0.70	[0.64; 0.75]	1.9%
20	229	263		0.87	[0.82; 0.91]	1.9%
21	19	21		- 0.90	[0.70; 0.99]	1.2%
22	116	182		0.64	[0.56; 0.71]	1.9%
23	253	284		0.89	[0.85; 0.92]	1.9%
24	531	632		0.84	[0.81; 0.87]	1.9%
25	228	300		0.76	[0.71; 0.81]	1.9%
26	41	56		0.73	[0.60; 0.84]	1.8%
27	375	488		0.77	[0.73; 0.81]	1.9%
28	115	152		0.76		1.9%
29 30	207	2211		0.65	[0.01, 0.09]	2.0%
31	60	182		0.33	[0.45, 0.47]	1.9%
32	319	438		0.73	[0.68: 0.77]	1.9%
33	164	194		0.85	[0.79; 0.89]	1.9%
34	377	592	:	0.64	[0.60; 0.68]	2.0%
35	26	60		0.43	[0.31; 0.57]	1.8%
36	179	201	: 🛨	0.89	[0.84; 0.93]	1.9%
37	189	364	<u> </u>	0.52	[0.47; 0.57]	1.9%
38	103	125	:	0.82	[0.75; 0.89]	1.9%
39	528	557	+	0.95	[0.93; 0.96]	1.9%
40	42	64		0.66	[0.53; 0.77]	1.8%
41	163	200		0.82	[0.75; 0.87]	1.9%
42	00 122	304		0.40	[0.36; 0.36]	1.9%
43 44	122	314	_	0.31	[0.20, 0.30]	1.9%
45	252	332	-	0.14	[0.10, 0.10]	1.9%
46	81	140		0.58	[0.49: 0.66]	1.9%
47	84	144		0.58	[0.50; 0.66]	1.9%
48	99	389	-	0.25	[0.21; 0.30]	1.9%
49	359	453		0.79	[0.75; 0.83]	1.9%
50	116	438	+ :	0.26	[0.22; 0.31]	1.9%
51	37	120		0.31	[0.23; 0.40]	1.9%
52	107	127	:	0.84	[0.77; 0.90]	1.9%
53	153	194		0.79	[0.72; 0.84]	1.9%
Random effects mode		22,603	· · · · · · · · · · · · · · · · · · ·	0.70	[0.64; 0.75]	100.0%
Heterogeneity: $I^2 = 98\%$,	$\tau^{-} = 0.9410, p = 0$, i 0	0.2 0.4 0.6 0.8	1		
		0	% Adherence			

Figure 3. Pooled proportion of PLHIV adhering to antiretroviral therapy in Latin America and Caribbean, 2005–2016. Cl, confidence interval; l^2 , the percentage of total variation across studies that is due to heterogeneity rather than chance; τ^2 , tau-squared is an estimate of the between-study variance; *p*, *p*-value.

(a) 3-4 days

Study	# Adherents	Total		Adherence %	95% CI	Weight
Amico et al., 2005	156	196	-	0.80	[0.73; 0.85]	9.8%
Balandrán et al., 2013	1783	2054	: +	0.87	[0.85; 0.88]	11.0%
Bonolo et al., 2005	193	306		0.63	[0.57; 0.68]	10.5%
Gutierrez et al., 2012	253	284	: 🕂	0.89	[0.85; 0.92]	9.6%
Hanif et al., 2013	531	632		0.84	[0.81; 0.87]	10.6%
llias et al., 2011	41	56	<u>.</u>	0.73	[0.60; 0.84]	7.9%
Remien et al., 2007	163	200		0.82	[0.75; 0.87]	9.7%
Silveira et al., 2014	252	332	- + ÷	0.76	[0.71; 0.80]	10.4%
Tietzmann et al., 2013	359	453		0.79	[0.75; 0.83]	10.6%
Zulliger et al., 2015	153	194	-	0.79	[0.72; 0.84]	9.8%
Random effects model		4707	<u> </u>	0.80	[0.74; 0.85]	100.0%
Heterogeneity: $I^2 = 93\%$, τ	² = 0.2196, <i>p</i> <	0.01 0	0.2 0.4 0.6 0.8 1	1		
			% Adherence			



(c) 30 days

Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.4441$, p < 0.01



Figure 4. Pooled proportion of PLHIV adhering to ART in LAC by adherence recall time frame, 2005–2016. (a) 3–4 days; (b) seven days; (c) 30 days, (d) 90 days. CI, confidence interval; l^2 , the percentage of total variation across studies that is due to heterogeneity rather than chance; τ^2 , tau-squared is an estimate of the between-study variance; p, p-value.

% Adherence

0 0.2 0.4 0.6 0.8 1



Figure 5. Pooled proportion of PLHIV adhering to ART in Brazil, 2005–2016. CI, confidence interval; l^2 , the percentage of total variation across studies that is due to heterogeneity rather than chance; τ^2 , tau-squared is an estimate of the between-study variance; p, p-value.

study provides better health care (e.g. ideal trial conditions and adherence counselling). In higher-income countries, where people may have access to a better public service or can afford for a private service, other factors beyond poverty can affect ART adherence (e.g. depression and substance misuse). Bezabhe et al. (2016) [21] when exploring the impact of adherence on virological failure found that the pooled odds ratio for virological suppression among those with optimal adherence compared to suboptimal adherence for countries with low HDI (0.50; 95% CI: 0.35-0.72) was lower than for countries with very high-HDI (0.23; 95% CI: 0.15-0.33). Suggesting that although adherence may be similar or higher, the expected effect of adherence on virologic suppression is lower in low/middle income countries. A possible explanation might be the lack of consistent virological monitoring [99] with patients adhering to non-suppressive treatment.

Measures of adherence include individual self-report, pharmacy records, pill counts, electronic measurement devices, therapeutic drug concentrations and clinical outcomes. The easiest and therefore most frequently used method is patient self-report. Self-report questions consider the number or frequency of doses missed/taken, or simply asks individuals to rate their adherence level, always considering a specific time period. Questionnaires frequently use a Likert-type scale as the response format (often five-point ordered response ranging from the most positive to the most negative response to a statement). Although individual self-report can be inexpensive, easy to administer, and accurately identify medication-taking behaviour [100], they may also overestimate adherence due to social desirability (i.e. respondents answer questions in a way that will be viewed favourably by clinicians) and recall biases [101]. These biases may have impacted our results, because patient's self-reported adherence was the most common method for assessing adherence in this meta-analysis. Self-report questionnaires, which have a reasonable predictive power, are useful for resource-limited clinical settings. The ACTG Adherence Questionnaire was the most extensively used instrument. It is a 5-item self-report measure, but frequently, only the first item (four-day recall of how many doses have been missed) is used in clinical setting. The CEAT-VIH was the second most used self-report instrument. The CEAT-VIH is a short (20 items) multidimensional self-report instrument to measure adherence, available in six languages: English, European Spanish and Latin American Spanish, European Portuguese, Brazilian Portuguese and Romanian. Although MEMS has been used as measure of choice to

Table 3. Subgroup analysis of studies included in the meta-analysis of adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean, 2005–2016

Analysis group	No of Studies	Sample size	Pooled Adherence (95% CI)	Tests for Heterogeneity	/
				p-value (Q Statistic) ^f	l ² (%)
Overall	53	22603	0.70 (0.64, 0.75)	<0.01	98
Time frame					
3–4 days	10	4707	0.80 (0.74, 0.85)	<0.01	93
7 days	13	6853	0.71 (0.57, 0.82)	< 0.01	98
30 days	15	8348	0.73 (0.58, 0.85)	< 0.01	99
90 days	4	948	0.55 (0.26, 0.81)	<0.01	96
Location/country					
Brazil	24	5712	0.64 (0.54, 0.73)	< 0.01	98
SA (Chile, Colombia, Peru)	12	3754	0.71 (0.49, 0.87)	< 0.01	99
CA/Caribbean (Cuba, DR, Guatemala, Haiti, Jamaica)	7	2100	0.79 (0.73, 0.85)	< 0.01	80
NA (Mexico, Puerto Rico)	5	2980	0.79 (0.47, 0.94)	< 0.01	98
Multi-site	5	8057	0.66 (0.44, 0.82)	< 0.01	100
Study period					
≤2005	5	1396	0.68 (0.39, 0.87)	< 0.01	98
2006–2010	24	7328	0.71 (0.60, 0.79)	< 0.01	97
≥2011	12	10025	0.66 (0.45, 0.82)	< 0.01	99
 Study design					
Cross-sectional	43	19257	0.69 (0.62, 0.76)	< 0.01	99
Longitudinal	6	2405	0.75 (0.38, 0.94)	< 0.01	98
RCT	4	941	0.66 (0.39, 0.86)	< 0.01	94
Country's income level ^a					
Low/Lower middle	3	804	0.83 (0.63, 0.93)	< 0.01	81
Upper middle	43	13426	0.70 (0.62, 0.77)	< 0.01	98
High	2 ^c				
Mix	5	8057	0.66 (0.44, 0.82)	< 0.01	100
HDIp	-		,		
<0.754	21	12736	0.75 (0.64, 0.84)	< 0.01	99
>0.754	31	9671	0.66 (0.57, 0.74)	< 0.01	98
GNI per capita ^b	01	, , , ,		0.01	, 0
<14145	23	13791	0.75 (0.65, 0.83)	<0.01	99
>14145	29	8616	0.65 (0.55, 0.74)	< 0.01	98
Sites			(,,		
Single	27	6579	0.65 (0.52, 0.76)	<0.01	98
Multi	23	11585	0.77 (0.70, 0.82)	<0.01	96
Online	3	4440	0.55 (0.31, 0.76)	< 0.01	98
Treatment experience	0			0.01	, 0
Naïve	3	510	0.56 (0.33, 0.78)	<0.01	75
Experienced	48	20594	0.69 (0.62, 0.75)	<0.01	, e 98
Naïve and experienced	2°		,,		
Instrument to measure adherence	-				
Self-report	49	21974	0.71 (0.64, 0.77)	0.02	99
MEMS	2°	21// 1	0.7 1 (0.0 1, 0.7 7)	0.02	,,,
Self-report+Withdrawal ^d	ے 1 ^c				
Self-report+Pill Count ^e	1 ^C				
Adherence threshold	Ť				
<94%	10	1897	072 (051 084)	<0.01	QQ
95%	18	7777	0.72 (0.66, 0.85)	<0.01	97
	TO	////	0.77 (0.00, 0.00)	-0.0 I	//

Table 3. (Continued)

Analysis group	No of Studies	Sample size	Pooled Adherence (95% CI)	Tests for Heterogeneity	/
				p-value (Q Statistic) ^f	l ² (%)
100%	11	5966	0.75 (0.62, 0.84)	<0.01	98
Not reported	14	6963	0.53 (0.40, 0.66)	< 0.01	99
Statistical models evaluating factors associated with ac	therence				
Yes	24	11425	0.70 (0.60, 0.78)	< 0.01	98
No	29	11178	0.70 (0.60, 0.79)	<0.01	99

CA, Central America countries; CI, confidence interval; DR, Dominican Republic; GNI, Gross National Income; HDI, United Nations human development index; MEMS, medication event monitoring system; NA, not applicable to SA or CA; RCT, randomized clinical trials; SA, South American countries.

^aStudy countries were categorized according to the income group, as defined by the World Bank for 2017 [22].

^bStudy countries were categorized according to the United Nations Human Development Index (HDI) ranking and the Gross National Income (GNI) per capita (based on purchasing power parity in constant 2011 international dollars), as defined by the United Nations Development Programme [3]. When a study involved multiple countries, the lower HDI or GNI value was considered.

°When the number of studies in each group was ≤2, meta-analysis was not performed.

^dUsed two methods to measure adherence, self-report or medication withdrawal, to calculate study proportion of participants in optimal adherence.

^eUsed two methods to measure adherence, self-report and pill count, to calculate study proportion of participants in optimal adherence.

 ^{f}p -value for the Q statistic hypothesis test of whether there is heterogeneity, a p-value <0.05 implies a rejection of the null hypothesis that the studies are homogeneous.

validate adherence measures such as patient's self-report or pharmacy database (medication withdrawal or refill data), the cost of this device substantially impairs its widespread use. Clinical outcomes, is considered by some researchers as one of the best measures of a patient's adherence behaviour, but the use of clinical outcomes as a proxy of adherence can always be biased by the presence of any patient- or diseaserelated factor. Each adherence measurement strategy has strengths and weaknesses. The best measurement strategy for clinical practice should take in consideration the setting, the population, and most importantly have acceptable reliability and validity.

We found that the assessment of the quality of the published studies was sometimes challenging. Many studies did not report relevant methodological details about the assessment of adherence, making it difficult to judge the strength of their findings. The absence of these data may have introduced a possible bias in the results (data retrieval bias). To promote improvement in the quality of measurement of medication adherence in research Williams et al. [102] have proposed a set of best practices for conducting adherence measurement. For studies using self-report, for example, it is recommended the use of an instrument and method of administration that demonstrate both concurrent and predictive validity. When using a new instrument, it needs to be validated in a pilot test. When a scale is used to measure adherence, it needs to be culturally sensitive, worded clearly, and subjects need to know how to respond to the scaling response options with little difficulty. In addition to their recommendations, and to improve also the reporting of adherence measurement, we suggest that researchers clearly identify the instrument used, whether it was validated for use in the study population, when the assessment was carried out (date), the adherence recall time frame used, the adherence definition used (i.e. no. of pills

taken/prescribed or instrument score), the optimal adherence cutoffs or thresholds adopted and ART used, which can greatly affect adherence to ART. Accurate assessment of adherence behaviour is essential for treatment planning while accurate reporting of adherence studies is essential for further advancement of the subject.

Identifying specific barriers for patients and implementing appropriate interventions to overcome them is extremely necessary to improve adherence. The social support was one of the factors associated with adherence in this systematic review and meta-analysis. Social network and social influence, can provide a powerful approach for health behaviour change [103]. Alcohol use was associated with nonadherence to ART in many studies. This association has been observed previously, where alcohol abuse can be higher in PLHIV than in the general population, and may lead to medical and psychiatric complications, poor adherence and poorer treatment outcomes [104]. In addition, alcohol use is associated with intravenous drug use and risky sexual behaviour, major modes of HIV transmission [104]. Unemployment was another barrier to nonadherence in LAC countries. This association exists globally, and was recently estimated with a pooled odds ratio of 1.27 (95% CI: 1.04–1.55) in a meta-analysis carried out by Nachega et al. (2015) [105]. Reporting of traditional barriers to ART such as toxicity and pill burden has reduced over time since current ART regimens are simpler and better tolerated. Consequently, the primary individual barriers to adherence have changed. In a recent meta-analysis conducted by Shubber et al. (2016) [106], individual barriers most frequently reported by patients included forgetting, being away from home, and a change to daily routine. Depression, alcohol/substance misuse, stigma, feeling sick, health service-related barriers (i.e. distance to clinic) and stock outs were less frequently reported. In this systematic review and metaanalysis studies reported many traditional barriers, in particular those related with alcohol and substance misuse. The presence of so many traditional barriers may be indictments that regimens in use in LAC are not aligned with WHO, PAHO and other agencies efforts to optimize drug regimens. In 2012, 4% of the patients of the region, approximately 30,000 patients out of the 725,000 that receive ART, were being treated with obsolete or inappropriate ARVs [107]. Also, in many countries the number of regimens in use still exceeds 15–20 [108].

This study has important limitations worth noting. Metaanalysis of observational studies, unlike randomized controlled trials, are prone to biases including confounding. The high risk of selection biases within included studies may be a function of their observational design. Moreover, we found high heterogeneity among the studies indicating that adherence varied significantly across studies, possibly due to different populations, different thresholds, different time frames and methods of measurement. Accordingly, random effects models were chosen as our analytical framework to better accommodate the heterogeneity since it assumes that each study was drawn from populations that differ from each other in ways that could impact the proportion of adherents. Heterogeneity was not entirely explained by subgroup analysis. A metaregression could help investigate the sources of the heterogeneity across studies by studying the relationship between study-level characteristics and adherence to ART, but it was not performed in this study due to discrepancies associated with reporting of participants' characteristics. For example, we were not able to evaluate a possible relationship between adherence and different regimens because this information was rarely available among the included studies. Another limitation is that most of the studies included in this meta-analysis used a cross-sectional design, making it difficult to determine causal relationships between level of adherence and other factors. Lastly, we did not include grey literature and therefore may have missed studies that were relevant to our research question during the literature search. However, the inclusion of grey literature may itself introduce biases if the studies found were not representative of all unpublished studies. Though, our results must be interpreted with caution, considering our assumptions and limitations, meta-analyses are still the preferred methodology in providing a qualitative interpretation of the results [109].

5 | CONCLUSIONS

In conclusion, our study suggests that PLHIV in LAC can achieve comparable adherence levels to other populations of developing regions though it may be below the sufficient levels required for successful long-term viral load suppression. Monitoring ART adherence is critical to provide information about possible causes of virological failure in LAC, where viral load testing is often carried out less frequently than regional guidelines recommend [99]. We encourage initiatives for improving ART adherence that consider the social determinants of health inside each context, involving communitybased organizations and social participation to address the huge socio-economic disparities and the health inequities present across and within LAC countries.

AUTHORS' AFFILIATIONS

Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

COMPETING INTERESTS

The authors declare that they have no competing interests.

AUTHORS' CONTRIBUTIONS

All authors contributed extensively to the work presented in this paper. JMC, TST, PML conceived the study. JMC, TST and PML created and performed the literature search strategy, JMC built the data extraction file, JMC and TST performed the data extraction and PML supervised the process. PML and LEC performed the statistical analyses, and all authors interpreted the data. JMC drafted the manuscript, and all the other authors contributed substantially to the writing and revising of the manuscript. All authors have read and approved the final version of the manuscript.

ACKNOWLEDGEMENTS

Funding sources

This work was conducted during a scholarship (JMC) supported by CAPES (Brazilian Federal Agency for Support and Evaluation of Graduate Education within the Ministry of Education of Brazil) and FAPERJ (Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro) at the Instituto Nacional de Infectologia Evandro Chagas - Fiocruz (Brazilian National Institute of Infectious Diseases). PML acknowledges funding from the National Council of Technological and Scientific Development and FAPERJ.

REFERENCES

1. Population of Latin America and the Caribbean. 2017, Worldometers [Internet]. [cited 2017 Dec 3]. Available from: http://www.worldometers.info/worldpopulation/latin-america-and-the-caribbean-population/

2. Report for selected country groups and subjects [Internet]. [cited 2017 Dec 3]. Available from: http://www.imf.org/external/pubs/ft/weo/2017/02/weodata/ weorept.aspx?sy=2015&ey=2022&scsm=1&ssd=1&sort=country&ds=.&br=1&pr 1.x=44&pr1.y=5&c=205&s=NGDP_RPCH%2CNGDPD%2CPPPGDP%2CNGDP RPPPPC%2CPPPPC%2CPPPSH%2CNID_NGDP%2CNGSD_NGDP&grp=1&a=1

3. United Nations Development Programme. Human development reports [Internet]. 2016 [cited 2017 Apr 28]. Available from: http://hdr.undp.org/en/com posite/HDI

4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. **1998**;338(13):853–60.

5. UNAIDS, AIDSinfo. Indicators [Internet]. [cited 2017 Jul 27]. Available from: http://aidsinfo.unaids.org/#

6. Rebeiro PF, Cesar C, Shepherd BE, De Boni RB, Cortés CP, Rodriguez F, et al. Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression. J Int AIDS Soc [Internet]. 2016 Apr 8 [cited 2017 Aug 7];19(1). Available from: http://www.jiasociety.org/index.php/jia s/article/view/20636

7. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global aids update - 2017. Ending AIDS. Progress towards the 90–90–90 targets. 2017.

8. United Nations. Political declaration on HIV and AIDS: on the fast-track to accelerate the fight against HIV and to end the AIDS epidemic by 2030. General Assembly. Seventieth session. Agenda item 11. Resolution A/RES/70/266 Jun 22, 2016.

9. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.

10. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang C, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.

11. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.

12. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40 (1):158–63.

13. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.

14. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45(1):4–8.

15. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45 (3):372–9.

16. Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, et al. Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2015;69 (4):493–8.

17. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. [Internet]. 2016 [cited 2017 Jan 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK374294/

18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

19. Costa J, Torres T, Coelho L, Luz P. Adherence to antiretroviral therapy for HIV/aids in Latin America and the Caribbean: a systematic review and metaanalysis. PROSPERO 2017:CRD42017055963 [Internet]. 2017. Available from: http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CR D42017055963

20. Kim S-H, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS. 2014;28(13):1945–56.

21. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore). 2016;95(15):e3361.

22. World Bank. List of economies [Internet]. 2017 [cited 2017 Apr 4]. Available from: databank.worldbank.org/data/download/site-content/CLASS.xls

23. Kim SY, Park JE, Lee YJ, Seo H-J, Sheen S-S, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66(4):408–14.

24. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] [Internet]. The Cochrane Collaboration; 2011. Available from: www.handbook.cochrane.org

25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

26. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

27. Bonolo PF, César CC, Acurcio FA, Ceccato MGB, Padua CAM, Alvares J, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005;19(Suppl 4):S5–13.

28. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005;19(Suppl 4):S14–21.

29. Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005;17(6):661–73.

30. Garcia R, Badaro R, Netto EM, Silva M, Amorin FS, Ramos A, et al. Crosssectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients. AIDS Res Hum Retroviruses. 2006;22(12):1248–52.

31. Remien RH, Bastos FI, Jnr VT, Raxach JC, Pinto RM, Parker RG, et al. Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil. AIDS Care. 2007;19(6):740–8.

32. Carvalho CV, Merchan-Hamann E, Matsushita R. Determinants of antiretroviral treatment adherence in Brasilia, Federal District: a case-control study. Rev Soc Bras Med Trop. 2007;40(5):555–65.

33. Mascolini M, Zuniga J. Perceptions of health, HIV disease, and HIV treatment by patients in 6 regions: analysis of the 2555-person AIDS treatment for life international survey. J Int Assoc Physicians AIDS Care Chic. 2008;7(4):160–77.

34. Piña Lopez JA, Davila Tapia M, Jose Sanchez-Sosa J, Togawa C, Cazares Robles O. Association between stress and depression levels and treatment adherence among HIV-positive individuals in Hermosillo, Mexico. Rev Panam Salud Publica. 2008;23(6):377–83.

35. Sepúlveda Carrillo G, Zúñiga ÁM, Amaya GA, Arévalo WL, Arias J, Carrillo PA, et al. Características sociodemográficas y determinantes de adhesión terapéutica antirretrovial en pacientes con VIH/SIDA en dos instituciones de Bogotá. Rev Colomb Enferm [Internet]. 2009;4(4). Available from: http://www. uelbosque.edu.co/sites/default/files/publicaciones/revistas/revista_colombiana_en fermeria/volumen4/caracteristicas_sociodemograficas_determinantes_adhesion_te rapeutica antirretroviral pacientes vih sida.pdf

36. Arrivillaga M, Ross M, Useche B, Lucia Alzate M, Correa D. Social position, gender role, and treatment adherence among Colombian women living with HIV/AIDS: social determinants of health approach. Rev Panam Salud Publica. 2009;26(6):502–10.

Campbell JI, Ruano AL, Samayoa B, Estrado Muy DL, Arathoon E, Young B. Adherence to antiretroviral therapy in an urban, free-care HIV clinic in Guatemala City, Guatemala. J Int Assoc Physicians AIDS Care Chic. 2010;9(6):390–5.
 Allen CF, Simon Y, Edwards J, Simeon DT. Adherence to antiretroviral therapy by people accessing services from non-governmental HIV support organisa-

tions in three Caribbean countries. West Indian Med J. 2011;60(3):269–75. 39. Aragonés C, Sánchez L, Campos JR, Pérez J. Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba. MEDICC Rev. 2011;13(2):17–23.

40. Cardona-Arias J, Peláez-Vanegas L, López-Saldarriaga J, Duque-Molina M, Leal-Álvarez O. Calidad de vida relacionada con la salud en adultos con VIH/ sida, Medellín, Colombia, 2009. Biomedica. 2011;31(4):532–44.

41. Casotti JAS, Mendes AAS, Endlich BN, Tartaglia RS, Queiroz MD, Motta TQR. Factors associated with adherence to HAART in patients with HIV/aids. DST J Bras Doenças Sex Transm [Internet]. 2011;23(4). Available from: http://www.dst. uff.br/revista23-4-2011/13.Factors%20associated%20with%20adherence.pdf

42. Harris J, Pillinger M, Fromstein D, Gomez B, Garris I, Kanetsky PA, et al. Risk factors for medication non-adherence in an HIV infected population in the Dominican Republic. AIDS Behav. 2011;15(7):1410–5.

 Hias M, Carandina L, Marin MJS. Adesão à terapia antirretroviral de portadores do vírus da imunodeficiência humana atendidos em um ambulatório da cidade de Marília, São Paulo. Rev Baiana Saúde Pública [Internet].
 2011;35(2). Available from: http://files.bvs.br/upload/S/0100-0233/2011/ v35n2/a2470.pdf

44. Muñoz M, Bayona J, Sanchez E, Arevalo J, Sebastian JL, Arteaga F, et al. Matching social support to individual needs: a community-based intervention to improve HIV treatment adherence in a resource-poor setting. AIDS Behav. 2011;15(7):1454–64.

45. Costa TM, Barbosa BJ, Gomes e Costa DA, Sigulem D, de Fátima Marin H, Filho AC, et al. Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages. Int J Med Inf. 2012;81(4):257–69.

46. Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, Solomon S, et al. HIV treatment adherence, patient health literacy, and health care provider-patient communication: results from the 2010 AIDS Treatment for Life International Survey. J Int Assoc Physicians AIDS Care Chic. 2012;11(2):128–33.

47. Gutierrez EB, Sartori AMC, Schmidt AL, Piloto BM, Franca BB, de Oliveira AS, et al. Measuring adherence to antiretroviral treatment: the role of pharmacy records of drug withdrawals. AIDS Behav. 2012;16(6):1482–90.

 Alave J, Paz J, González E, Campos M, Rodríguez M, Willig J, et al. Factores asociados a falla virológica en pacientes infectados con VIH que reciben terapia anti-retroviral en un hospital público del Perú Rev Chil Infectol. 2013;30(1):42–8.
 Hanif H, Bastos FI, Malta M, Bertoni N, Surkan PJ, Winch PJ, et al. Individual and contextual factors of influence on adherence to antiretrovirals among people attending public clinics in Rio de Janeiro, Brazil. BMC Public Health. 2013;13:574.

50. Malow R, Dévieux JG, Stein JA, Rosenberg R, Jean-Gilles M, Attonito J, et al. Depression, substance abuse and other contextual predictors of adherence to antiretroviral therapy (ART) among Haitians. AIDS Behav. 2013;17(4):1221–30.

51. de Padoin SMM, Zuge SS, dos Santos ÉEP, Primeira MR, Aldrighi JD, de Paula CC. Adesão à terapia antirretroviral para HIV/AIDS*. Cogitare Enferm. 2013;18(3):446–51.

52. Teixeira C, Dourado Mde L, Santos MP, Brites C. Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia, Brazil. AIDS Res Hum Retroviruses. 2013;29(5):799–804.

53. Tietzmann DC, Béria JU, dos Santos GM, Mallmann DA, Trombini ES, Schermann LB. Prevalências de adesão à terapia antirretroviral e fatores associados em pacientes adultos de três centros urbanos do Sul do Brasil. Aletheia. 2013;41:154–63.

54. Varela-Arévalo MT, Gómez Gutiérrez OL, Mueses Marían HF, Galindo Quintero J, Tello Bolívar IC. Factores relacionados con la adherencia al tratamiento farmacológico para el VIH/SIDA. Salud Uninorte. 2013;29(1):83–95. 55. Basso CR, Santa Helena ET, Magalhaes Caraciolo JM, Paiva V, Battistela Nemes MI. Exploring ART intake scenes in a human rights-based intervention to improve adherence: a randomized controlled trial. AIDS Behav. 2013;17(1):181–92.

56. Balandrán DA, Gutiérrez JP, Romero M. Evaluación de la adherencia antirretroviral en México: adherencia de cuatro días vs. índice de adherencia. Rev Invest Clin. 2013;65(5):384–91.

57. Calvetti PÜ, Giovelli GRM, Gauer GJC, de Moraes JFD. Psychosocial factors associated with adherence to treatment and quality of life in people living with HIV/AIDS in Brazil. J Bras Psiquiatr. 2014;63(1):8–15.

58. Ivers LC, Teng JE, Jerome JG, Bonds M, Freedberg KA, Franke MF. A randomized trial of ready-to-use supplementary food versus corn-soy blend plus as food rations for HIV-infected adults on antiretroviral therapy in rural Haiti. Clin Infect Dis. 2014;58(8):1176–84.

59. de Jacques IJAA, de Santana JM, de Moraes DCA, de Souza AFM, da Abrão FMS, de Oliveira RC. Avaliação da Adesão à Terapia Antirretroviralentre Pacientes em Atendimento Ambulatorial. Rev Bras Ciênc Saúde. 2014;18 (4):303–8.

60. Silva A, Reis RK, Nogueira JA, Gir E. Quality of life, clinical characteristics and treatment adherence of people living with HIV/AIDS. Rev Lat Am Enferm. 2014;22(6):994–1000.

61. Varela M, Galdames S. Depresión y adhesión a terapia anti-retroviral en pacientes con infección por VIH atendidos en el Hospital San Pablo de Coquimbo, Chile. Rev Chil Infectol. 2014;31(3):323–8.

62. Silveira MPT, Guttier MC, Page K, Moreira LB. Randomized controlled trial to evaluate the impact of pharmaceutical care on therapeutic success in HIV-infected patients in Southern Brazil. AIDS Behav. 2014;18(Suppl 1):S75–84.

63. De La Hoz JM, Bolano L, Cardenas O, Gonzalez R, Sabbag J, Palacio L, et al. Characterization of treatment failure in HIV positive patients in the Colombian Caribbean region. Colomb Medica Cali Colomb. 2014;45(4):162–7.

64. Ferro EG, Weikum D, Vagenas P, Copenhaver MM, Gonzales P, Peinado J, et al. Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care. 2015;27(1):93– 104.

65. Krishnan A, Ferro EG, Weikum D, Vagenas P, Lama JR, Sanchez J, et al. Communication technology use and mHealth acceptance among HIV-infected men who have sex with men in Peru: implications for HIV prevention and treatment. AIDS Care. 2015;27(3):273–82.

66. Magidson JF, Biello KB, Safren SA, Rosenberger JG, Novak DS, Mayer KH, et al. Engagement in HIV care and sexual transmission risk behavior among men who have sex with men using online social/sexual networking in Latin America. AIDS Care. 2015;27(8):1055–62.

67. Malbergier A, do Amaral RA, Cardoso LD. Alcohol dependence and CD4 cell count: is there a relationship? AIDS Care. 2015;27(1):54–8.

68. Pérez-Salgado D, Compean-Dardón MS, Staines-Orozco MG, Ortiz-Hernández L. Satisfaction with healthcare services and adherence to antiretroviral therapy among patients with HIV attending two public institutions. Rev Invest Clin. 2015;67(2):80–8.

69. Santillán Torres Torija C, Villagrán Vázquez G, Robles Montijo SS, de Eguiluz Romo LL. The information and motivation and behavioral skills model of ART adherence among HIV-positive adults in Mexico. J Int Assoc Provid AIDS Care. 2015;14(4):335–42.

70. Tello-Velásquez JR, Díaz-Llanes BE, Mezones-Holguín E, Rodríguez-Morales AJ, Huamaní C, Hernández AV, et al. La mala calidad de sueño se asocia a una menor adherencia al tratamiento antirretroviral de gran actividad en pacientes peruanos con infección por VIH/SIDA. Cad Saude Publica. 2015;31(5):989–1002.

71. Tufano CS, Amaral RA, Cardoso LR, Malbergier A. The influence of depressive symptoms and substance use on adherence to antiretroviral therapy. A cross-sectional prevalence study. Sao Paulo Med J. 2015;133 (3):179–86.

72. Zulliger R, Barrington C, Donastorg Y, Perez M, Kerrigan D. High drop-off along the HIV care continuum and ART Interruption among female sex workers in the Dominican Republic. J Acquir Immune Defic Syndr. 2015;69(2):216–22.

73. Pacifico J, Gutierrez C. Information about the medicines and adherence to high activity antiretroviral treatment in patients with HIV/AIDS in a hospital of Lima, Peru. Rev Peru Med Exp Salud Publica. 2015;32(1):66–72.

74. Magidson JF, Li X, Mimiaga MJ, Moore AT, Srithanaviboonchai K, Friedman RK, et al. Antiretroviral medication adherence and amplified HIV transmission risk among sexually active HIV-infected individuals in three diverse international settings. AIDS Behav. 2016;20:699–709.

75. Drachler M, Drachler CW, Teixeira LB, Leite JC. The scale of self-efficacy expectations of adherence to antiretroviral treatment: a tool for identifying risk for non-adherence to treatment for HIV. PLoS ONE. 2016;11(2):e0147443.

76. de Souza GO, Tibúrcio AACM, Koike MK. Appropriate adherence to antiretroviral therapy in the Alto Paranaiba, Minas Gerais, Brazil. Med Expr. 2016;3(3):M160305.

77. De Boni RB, Shepherd BE, Grinsztejn B, Cesar C, Cortes C, Padgett D, et al. Substance use and adherence among people living with HIV/AIDS receiving cART in Latin America. AIDS Behav. 2016;20:2692–9.

78. Biello KB, Oldenburg CE, Rosenberger J, Mayer KH, Novak D, Mimiaga MJ. Is involvement in sex work associated with engagement in HIV-related medical care in Latin American men who have sex with men? Results of a large. Multinational Internet Survey. LGBT Health. 2016;3(3):233–7.

79. Fleming PJ, Barrington C, Perez M, Donastorg Y, Kerrigan D. HIV testing, care, and treatment experiences among the steady male partners of female sex workers living with HIV in the Dominican Republic. Aids Care-Psychol Socio-Med Asp AidsHiv. 2016;28(6):699–704.

80. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care. 2000;12 (3):255–66.

81. Varela MT, Salazar IC, Correa D, Duarte C, Tamayo JA, Salazar ÁE. La evaluación integral de la adherencia al tratamiento en mujeres con VIH/SIDA: validación de un cuestionario. Colomb Médica. 2009;40(4):387–98.

82. Remor E. Systematic review of the psychometric properties of the questionnaire to evaluate the adherence to HIV therapy (CEAT-VIH). Patient. 2013;6 (2):61–73.

83. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24 (1):67–74.

84. Duong M, Piroth L, Grappin M, Forte F, Peytavin G, Buisson M, et al. Evaluation of the Patient Medication Adherence Questionnaire as a tool for selfreported adherence assessment in HIV-infected patients on antiretroviral regimens. HIV Clin Trials. 2001;2(2):128–35.

85. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16(4):605–13.

86. Piña López JA, Corrales Rascón AE, Mungaray Padilla K, Valencia Vidrio MA. Instrumento para medir variables psicológicas y comportamientos de adhesión al tratamiento en personas seropositivas frente al VIH (VPAD-24). Rev Panam Salud Publica. 2006;19(4):217–28.

87. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a metaanalysis. JAMA. 2006;296(6):679–90.

88. Mhaskar R, Alandikar V, Emmanuel P, Djulbegovic B, Patel S, Patel A, et al. Adherence to antiretroviral therapy in India: a systematic review and meta-analysis. Indian J Community Med. 2013;38(2):74.

89. Ortego C, Huedo-Medina TB, Vejo J, Llorca FJ. Adherence to highly active antiretroviral therapy in Spain. A meta-analysis. Gac Sanit. 2011;25 (4):282–9.

90. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodríguez E, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381–96.

91. Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731–47.

92. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012;26(16):2039–52.

93. Mountain E, Mishra S, Vickerman P, Pickles M, Gilks C, Boily MC. Antiretroviral therapy uptake, attrition, adherence and outcomes among HIV-infected female sex workers: a systematic review and meta-analysis. PLoS ONE. 2014;9 (9):e105645.

94. Uthman OA, Oladimeji O, Nduka C. Adherence to antiretroviral therapy among HIV-infected prisoners: a systematic review and meta-analysis. AIDS Care. 2016;29:1–9.

95. Huan Z, Fuzhi W, Lu L, Min Z, Xingzhi C, Shiyang J. Comparisons of adherence to antiretroviral therapy in a high- risk population in china: a systematic review and meta-analysis. PLoS ONE. 2016;11(1):e0146659.

96. Martin D, Luz PM, Lake JE, Clark JL, Campos DP, Veloso VG, et al. Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil. J Int AIDS Soc [Internet]. 2017 Jan 1 [cited 2017 Aug 17]; 20(1). Available from: http://www.jiasociety.org/index.php/jias/article/view/ 21405

97. Marmot M. The health gap: the challenge of an unequal world. Lancet. 2015;386(10011):2442–4.

98. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014;11(3):291–307.

99. Belaunzaran-Zamudio PF, Caro-Vega YN, Shepherd BE, Crabtree-Ramirez BE, Luz PM, Grinsztejn B, et al. Monitoring of HIV treatment in seven countries in the WHO Region of the Americas. Bull World Health Organ. 2015;93 (8):529–39.

100. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr. 1999;2002(31 Suppl 3):S103–6.

101. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(Suppl 2):S143–51.

102. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17 (1):284–97.

103. Latkin CA, Knowlton AR. Social network assessments and interventions for health behavior change: a critical review. Behav Med. 2015;41(3):90–7.

104. Petry NM. Alcohol use in HIV patients: what we don't know may hurt us. Int J STD AIDS. $1999;10(9):561{-}70.$

105. Nachega JB, Uthman OA, Peltzer K, Richardson LA, Mills EJ, Amekudzi K, et al. Association between antiretroviral therapy adherence and employment status: systematic review and meta-analysis. Bull World Health Organ. 2015;93 (1):29–41.

106. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. Weiser SD, editor. PLoS Med. 2016;13(11):e1002183. 107. Organização Pan-americana de Saúde. Antiretroviral treatment in the spotlight: a public health analysis in Latin America and the Caribbean. Washing-ton-DC: OPAS/PAHO; 2013.

108. Organização Pan-americana de Saúde. Antiretroviral treatment in the spotlight: a public health analysis in Latin America and the Caribbean 2014. Key Messages. Washington-DC: OPAS/PAHO; 2014.

109. Ioannidis JPA, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336(7658):1413–5.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Additional file 1 File in format docx. PubMed search strategy for studies of adherence to antiretroviral therapy for HIV/ AIDS in Latin America and the Caribbean.